Northview Acquisition's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Northview Acquisition in the second quarter 2026?
Due to the lack of equity, it was not possible to calculate Northview Acquisition Corp's return on equity (ROE) in its second quarter 2026

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Equity Change	-	-	-	-	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-27	-21	-19	-10	-10
Return On Equity (TTM)	-	-	-	-	-
NVAC's Total Ranking	#	#	#	#	#
Equity (TTM) in Millions	-27	-28	-27	-124	-122
Seq. Equity Change	-	-	-	-	-
Seq. Net Income Change	-	-	-	-	-

Back to NVAC Management Effectiveness >> NVAC's 5 Years Annual ROE >> Compare NVAC ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Equity Statistics
High	Average	Low
0 %	0 %	0 %

NVAC Annual Return On Equity	(Sep 30 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	-34	-13	-110	-1	-6
Y / Y Equity Change	-	-	-	-	-
Net Income in Millions	-22	-9	3	7	0
Y / Y Net Income Change	-	-	-53.97 %	2285.8 %	-
Return On Equity	-	-	-	-	-

Back to NVAC Management Effectiveness >> NVAC's 5 Years Annual ROE >> Compare NVAC ROE to its Competitors

Annual Roe Comment

Despite deterioration in net income, company improved ROE to in 2025, company improved ROE to 2285.8 % compared to the prior year.

More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
NVAC's' Return on Equity at Yahoo Finance
NVAC's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for NVAC's Competitors
Subscribers only: Roe for Northview Acquisition's Suppliers
Subscribers only: Return On Equity for NVAC's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Oncotelic Therapeutics Inc	124.17 %
Fortress Biotech Inc	118.22 %
Medpace Holdings Inc	110.15 %
Pulmatrix Inc	108.83 %
Arbutus Biopharma Corp	106.04 %
Rigel Pharmaceuticals Inc	96.49 %
Exelixis Inc	93.62 %
Alnylam Pharmaceuticals Inc	93.61 %
Eli Lilly And Company	92.54 %
Amgen Inc	89.32 %
Q32 Bio Inc	76.88 %
3m Company	76.55 %
Oramed Pharmaceuticals Inc	73.03 %
Tg Therapeutics Inc	72.30 %
Idexx Laboratories Inc	71.96 %
Elite Pharmaceuticals Inc	71.10 %
Zoetis Inc	68.87 %
Rallybio Corporation	68.56 %
Earth Science Tech Inc	66.17 %
Aurinia Pharmaceuticals Inc	59.00 %
Vaxart Inc	53.04 %
Qhslab Inc	51.21 %
Tenet Healthcare Corp	50.64 %
Nrc Health	48.29 %
Concentra Group Holdings Parent Inc	48.13 %
Bristol myers Squibb Company	46.65 %
Agilent Technologies inc	41.99 %
Eton Pharmaceuticals Inc	40.13 %
Adma Biologics Inc	39.59 %
Dexcom Inc	36.25 %

Date modified: 2026-09-26T07:41:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.